Cell Therapeutics' Pixuvri® Phase 3 Clinical Trial Results Published in The ... Equities.com The EMA's Committee for Medicinal Products for Human Use ("CHMP") has accepted PIX306, CTI's ongoing randomized controlled phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after one to ... |
